RVMD Stock Risk & Deep Value Analysis
Revolution Medicines Inc
DVR Score
out of 10
What You Need to Know About RVMD Stock
We analyzed Revolution Medicines Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RVMD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
RVMD Risk Analysis & Red Flags
What Could Go Wrong
Despite strong Phase 3 data, commercialization of a novel oncology drug in a competitive market is challenging. If daraxonrasib faces slow uptake, pricing pressures, or unexpected safety signals post-approval, the company's valuation, which is already stretched for a pre-commercial entity, could significantly retract.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Significant quarterly net loss ($453.8M in Q1 2026) indicating high cash burn, though funded for now.
- ⚠
Analyst average price target ($103.88) is currently below the current stock price, suggesting potential valuation concerns or lagging updates.
- ⚠
Heavy reliance on the successful commercialization of daraxonrasib for future revenue and profitability, typical of clinical-stage biotechs.
Upcoming Risk Events
- 📅
Regulatory delays or unexpected complete response letter from FDA (Potential H2 2026 - H1 2027)
- 📅
Unfavorable commercialization challenges or slow market adoption
- 📅
Competitor breakthroughs in RAS inhibition with superior efficacy or safety profiles
When to Reconsider
- 🚪
Failure to submit an NDA/BLA for daraxonrasib to regulatory agencies within 12 months.
- 🚪
Significant negative safety signals or unexpected efficacy issues emerge post-approval or in expanded trials.
- 🚪
Cash burn significantly accelerates beyond current projections without proportional revenue ramp-up or additional financing leads to excessive dilution.
Unlock RVMD Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Revolution Medicines is a high-conviction investment targeting a 10x return within 3-5 years due to its potentially transformative RAS(ON) inhibitor platform, headlined by daraxonrasib's exceptional Phase 3 overall survival data. The company is well-capitalized to navigate commercialization, poised for market leadership in a significant oncology segment, and represents a compelling opportunity for investors seeking exposure to groundbreaking cancer therapies despite its pre-commercial status and high current valuation.
Is RVMD Stock Undervalued?
Unlock the full AI analysis for RVMD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RVMD Price Targets & Strategy
12-Month Target
$220.00
Bull Case
$350.00
Bear Case
$100.00
Valuation Basis
Based on 4-5x projected peak sales of daraxonrasib across multiple indications (~$7-10B), risk-adjusted for regulatory approval, commercialization, and platform valuation.
Entry Strategy
Consider dollar-cost averaging on dips to the $135-$145 range, which represents a consolidation zone following the Phase 3 data announcement and before potential FDA filing.
Exit Strategy
Take 25% profit at $250, 25% at $300. Set a stop-loss at $120 to protect against unexpected negative news or regulatory setbacks.
Portfolio Allocation
7-10% for aggressive risk tolerance, 3-5% for moderate risk tolerance, acknowledging the high-risk, high-reward nature.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is RVMD Financially Healthy?
Valuation
P/E Ratio
-24.51
Forward P/E
-8.10
EV/EBITDA
-27.30
PEG Ratio
-1.20
Price/Book
8.40
Profitability
Operating Margin
-3145.03%
Net Margin
-2833.88%
Return on Equity
-54.06%
EPS
$-4.80
Balance Sheet
Current Ratio
7.14
Quick Ratio
6.97
Debt/Equity
0.16
Total Debt
$28.00M
Cash & Equivalents
$3.90B
Cash Flow
Operating Cash Flow
-$1.24B
Free Cash Flow
-$1.07B
EBITDA
-$1.03B
Other
Beta (Volatility)
1.40
Does RVMD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The strong Phase 3 data for daraxonrasib establishes a significant lead in the RAS(ON) inhibitor space, creating a patent-protected product with high efficacy. This scientific lead, combined with potential first-mover advantage and physician preference once established, contributes to a durable moat.
Moat Erosion Risks
- •Development of a superior RAS(ON) inhibitor by a competitor that enters the market faster or demonstrates better safety/efficacy.
- •Patent expiry or successful patent challenges could erode IP protection.
- •New therapeutic modalities or combination therapies could diminish the market opportunity for single-agent RAS(ON) inhibitors.
RVMD Competitive Moat Analysis
Sign up to see competitive advantages
RVMD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, fueled by excitement over the strong Phase 3 clinical trial results, but retail sentiment details not explicitly provided in real-time data.
Institutional Sentiment
Positive, with a 'Buy' consensus rating. However, the average price target ($103.88) appears to be lagging the latest Phase 3 data and is below the current stock price, indicating potential for significant upgrades as analysts update models.
Insider Activity (Form 4)
No specific Form 4 insider transactions (buying or selling) were verified in the provided sources for the last 90 days.
Options Flow
Normal options activity observed in the provided sources. No unusual institutional positioning or significant skew in put/call ratios was specifically verified.
Earnings Intelligence
Next Earnings
Estimated early-August 2026
Surprise Probability
Medium
Historical Earnings Pattern
With no product revenue, earnings reports historically focus on pipeline progress, R&D spend, and cash runway. Significant clinical milestones often drive larger stock price reactions than quarterly financial results alone.
Key Metrics to Watch
Competitive Position
Top Competitor
AMGN (Amgen)
Market Share Trend
Gaining ground, as daraxonrasib has the potential to be a best-in-class RAS(ON) inhibitor, carving out a new significant market segment within RAS-mutated cancers.
Valuation vs Peers
RVMD trades at a significant premium for a pre-commercial company, reflecting the perceived blockbuster potential of daraxonrasib. Larger, revenue-generating peers like Amgen or Mirati (pre-BMS acquisition) would have meaningful P/S multiples, which RVMD currently lacks.
Competitive Advantages
- •Superior clinical efficacy demonstrated in Phase 3 trials (HR 0.40 OS benefit).
- •Proprietary RAS(ON) inhibitor platform with potential for multiple drug candidates.
- •Strategic focus on a high unmet need oncology pathway (RAS-mutated cancers).
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive RVMD Stock Higher?
Near-Term (0-6 months)
- •Potential regulatory (FDA) filing for daraxonrasib (Expected within 6-12 months)
- •Presentation of detailed Phase 3 RASolute 302 data at major oncology conferences (Q2/Q3 2026)
- •Updates on other pipeline RAS(ON) inhibitors
Medium-Term (6-18 months)
- •Potential accelerated FDA approval and commercial launch of daraxonrasib (Expected 2027-2028)
- •Initiation of additional Phase 3 trials for daraxonrasib in other indications or earlier lines of therapy
- •Strategic partnerships for ex-US commercialization
Long-Term (18+ months)
- •Establishment of RAS(ON) inhibition as a standard of care across multiple cancer types
- •Successful development and commercialization of a multi-product RAS(ON) platform
- •Potential acquisition target by a large pharmaceutical company seeking oncology leadership
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for RVMD?
- ✓
Acceleration in daraxonrasib's regulatory approval timeline or expanded access programs.
- ✓
Positive readouts from other pipeline RAS(ON) programs, validating the platform.
- ✓
Faster-than-expected commercial ramp-up post-launch.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Revolution Medicines Inc Makes Money
Revolution Medicines is a biotechnology company focused on discovering, developing, and commercializing novel drugs for cancer. Their primary approach targets the RAS pathway, a key driver in many cancers, specifically developing RAS(ON) inhibitors. They currently generate no product revenue, operating primarily on capital raised through equity offerings and debt financing to fund extensive research and development (R&D) and clinical trials. Their business model aims to transition from a pure R&D-stage company to a commercial entity, generating revenue from the sales of approved oncology drugs to cancer patients globally.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Revolution Medicines Inc (RVMD)?
As of May 16, 2026, Revolution Medicines Inc has a DVR Score of 8.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Revolution Medicines Inc?
Revolution Medicines Inc's market capitalization is approximately $31.0B..
What is the risk level for RVMD stock?
Our analysis rates Revolution Medicines Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RVMD?
Revolution Medicines Inc currently has a price-to-earnings (P/E) ratio of -24.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is RVMD stock profitable?
Revolution Medicines Inc has a profit margin of -2833.9%. The company is currently unprofitable.
How often is the RVMD DVR analysis updated?
Our AI-powered analysis of Revolution Medicines Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RVMD (Revolution Medicines Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.